An interventional study of DBS programing in Essential Tremor, sponsored by Alfonso Fasano. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-11-04.
Sponsored by Alfonso Fasano · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Essential Tremor with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Tremor · Canada.
Among the 26 studies in Essential Tremor with a site in Canada, this one is the 14th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 22nd registered.
272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.
Browse Essential Tremor studies →8 of the 26 studies in Essential Tremor with a site in Canada are open now. Recruiting first, the newest first:
AbbVie · Sites in Canada, United States
Ages 18–85
University Health Network, Toronto · Sites in Canada
Ages 18–85 · Healthy volunteers
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 22+
University Health Network, Toronto · Sites in Canada
Ages 18+
Université de Sherbrooke · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 1
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 25 across 189 interventional studies indexed under Essential Tremor.
Median enrollment 22 across the 22 interventional studies, 370 across the 4 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 26 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Alfonso Fasano as lead sponsor.
Alfonso Fasano has 1 study filed under Essential Tremor — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Essential Tremor with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Population Size and Eligible Patients: The investigators aim to recruit 5 to 10 patients with tremors who have previously undergone Ventral Intermedius Deep Brain Stimulation (VIM-DBS) treatment but have experienced early or late loss of benefits. Additionally, the investigators will enroll ten patients with essential tremor who require VIM-DBS surgery. These individuals will undergo bilateral implantation of Boston Scientific Genus Implantable Pulse Generator (IPG) devices, connected to Boston Scientific Cartesia™ 8-contact Directional Leads.
Study Design: This study comprises two distinct phases. Phase 1 is a cross-sectional investigation designed to identify the optimal algorithm for patterned stimulation in the VIM region . Phase 2 is a prospective clinical trial focusing on the assessment of safety and efficacy of bilateral VIM-DBS in patients with essential tremor.
Objectives: The primary objective in Phase 2 is to evaluate the safety and effectiveness of bilateral VIM-DBS in individuals with essential tremor. In Phase 1, the investigators seek to explore the impact of the Chronos programming software on tremor patients who have experienced early or late loss of benefits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 to 10 patients with tremor already treated with VIM-DBS but not doing well because of early or late loss of benefits will be recruited by the PI over a 6 months period. If interested, the potential participants will be screened, informed, and consented by a research coordinator. Before the replacement of their IPG (implantable pulse generator), a baseline measurement will be performed.
Other: DBS programing
Ten patients with ET needing DBS-VIM surgery will be recruited and will receive Boston Scientific Genus IPG bilaterally connected to Boston Scientific Cartesia™ 8-contact Directional Leads. The programming will be done in four different settings/periods during the course of 8 months.
Other: DBS programing
The physician will utilize the Boston Scientific Chronos Clinician Programmer (software) to make adjustments to the Deep Brain Stimulation (DBS) settings for the patients.
Tremor Rating Scale (Part A-B)
Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.
Time frame: Phase 1-Baseline
Tremor analysis
Using accelerometers
Time frame: Phase 1-Baseline
Tremor Rating Scale (A-C)
Range from 0-46. with 0 representing no tremor and 46 representing severe tremor.
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Tremor analysis (meter per second squared)
Using accelerometers
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Gait speed (meter per second)
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Base of support (meter)
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Step length (meter)
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Stride length (meter)
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Single stance time and double stance time (seconds)
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Tandem gait
Gait Analysis
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Posturography (newtons)
Using Proteokinetics Zeno System
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Quality of life in Essential Tremor Questionnaire (QUEST)
Range from 0-40, with 0 representing no tremor and 40 representing severe tremor.
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Speech analysis
automated analysis pipeline in MatLab
Time frame: Phase 2-Baseline, Month 2, Month 4, Month 6, Month 8
Started Jul 2024 (actual). Primary completion is estimated for Apr 2026, 20 months after the start.
Of 77 non-industry interventional studies with no phase under Essential Tremor, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 26. This study's planned 20 months is below that.
Counting every sponsor, half of 95 studies reached it within 45 months; a quarter within 19 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.